GLP-1 and muscle mass preservation for women Women naturally have less muscle mass than men and can lose muscle more easily during weight loss
UPDATE: On January 8, 2024, Hangzhou Jiuyuan Gene Engineering became the second Chinese company to receive permission for the clinical trial of the class 3.3 biosimilar semaglutide for weight control, according to the website of the Center for Drug Evaluation (CDE)
Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases
Declarations Ethical statement This report followed CARE guidelines
Jensen SB, Janus C, Lundgren JR, et al
Through partnerships that include Augusta Universitys Medical College of Georgia, Wellstar helps educate future clinicians, accelerate discovery and translate research into real-world impact